Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.44
-0.34 (-1.91%)
At close: May 23, 2025, 4:00 PM
17.13
-0.31 (-1.78%)
After-hours: May 23, 2025, 6:48 PM EDT
Apellis Pharmaceuticals Employees
As of December 31, 2024, Apellis Pharmaceuticals had 710 total employees, including 705 full-time and 5 part-time employees. The number of employees increased by 4 or 0.57% compared to the previous year.
Employees
710
Change (1Y)
4
Growth (1Y)
0.57%
Revenue / Employee
$1,092,731
Profits / Employee
-$315,042
Market Cap
2.19B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
APLS News
- 4 days ago - Apellis Pharmaceuticals: Have Some Patience - Seeking Alpha
- 17 days ago - Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 18 days ago - Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 24 days ago - Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Apellis Announces Craig Wheeler to Join the Board of Directors - GlobeNewsWire
- 7 weeks ago - FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Benzinga
- 7 weeks ago - Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire